Highly versatile immunostimulating nanocapsules for specific immune potentiation

Nanomedicine

Volumn 9, Issue 15, 2014, Pages 2273-2289

  Vicente, Sara ^a,b,c   Peleteiro, Mercedes ^d   Gonzalez Aramundiz, Jose V ^a,b   Díaz Freitas, Belén ^d   Martínez Pulgarín, Susana ^e   Neissa, Jose I ^a   Escribano, Jose M ^f   Sanchez, Alejandro ^b,g   González Fernández, África ^d   Alonso, Maria J ^a,b,g  

^a Universidade de Santiago de Compostela and Instituto de Investigación Sanitaria de Santiago de Compostela   (Spain)

^b UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^c SANOFI   (France)

^d UNIVERSITY OF VIGO   (Spain)

^e UNIVERSIDAD POLITÉCNICA DE MADRID   (Spain)

^f INIA   (Spain)

^g Santiago University Clinical Hospital   (Spain)

Author keywords

adjuvants; antigen delivery; chitosan; hepatitis B; nanocapsules; squalene

Indexed keywords

GLUCOSAMINE DERIVATIVE; HEPATITIS B SURFACE ANTIGEN; IMIQUIMOD; INFLUENZA VIRUS HEMAGGLUTININ; NANOCAPSULE; POLYGLUCOSAMINE; SQUALENE; UNCLASSIFIED DRUG; ANTIBODY; IMMUNOLOGICAL ADJUVANT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOSTIMULATION; INTERNALIZATION; MEAN RESIDENCE TIME; MOUSE; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZE; ZETA POTENTIAL; ANIMAL; BAGG ALBINO MOUSE; BLOOD; ENZYME LINKED IMMUNOSORBENT ASSAY;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; MICE; MICE, INBRED BALB C; NANOCAPSULES;

EID: 84912066047     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.14.10     Document Type: Article

References (35)

1. Perrie Y, Mohamed AR, Kirby D, McNeill SE, Bramwell VW. Vaccine adjuvant systems: enhancing the efficacy of sub-unit protein antigens. Int. J. Pharm. 364, 272-280 (2008).
2. Vicente S, Prego C, Csaba N, Alonso MJ. From single-dose vaccine delivery systems to nanovaccines. J. Drug Deliv. Sci. Technol. 20, 267-276 (2010).
3. Correia-Pinto JF, Csaba N, Alonso MJ. Vaccine delivery carriers: Insights and future perspectives. Int. J. Pharm. 440, 27-38 (2013).
4. De Temmerman M, Rejman J, Demeester J, Irvine DJ, Gander B, De Smedt SC. Particulate vaccines: on the quest for optimal delivery and immune response. Drug Discov. Today 16, 569-582 (2011).
5. Fox CB. Squalene emulsions for parenteral vaccine and drug delivery. Molecules 14, 3286-3312 (2009).
6. Gomez-Casado E, Gomez-Sebastian S, Nunez MC, Lasa-Covarrubias R, Martinez-Pulgarin S, Escribano JM. Insect larvae biofactories as a platform for inf luenza vaccine production. Protein Expr. Purif. 79, 35-43 (2011).
7. Vicente S, Díaz B, Peleteiro M et al. A polymer/oil based nanovaccine as a single-dose immunization approach. PLoS ONE 8, e62500 (2013).
8. Paula DD, Martins CA, Bentley MVLB. Development and validation of HPLC method for imiquimod determination in skin penetration studies. Biomed. Chromatogr. 22, 1416-1423 (2008).
9. Vicente S, Peleteiro M, Díaz B, Sanchez A, González- Fernández A, Alonso MJ. Co-delivery of viral proteins and TLR7 agonist from polysaccharide nanocapsules: a needle-free vaccination strategy. J. Control. Release 172, 773-781 (2013).
10. Prego C, Torres D, Alonso MJ. Chitosan nanocapsules: a new carrier for nasal peptide delivery. J. Drug Deliv. Sci. Technol. 16, 331-337 (2006).
11. Tafaghodi M, Saluja V, Kersten GFA et al. Hepatitis B surface antigen nanoparticles coated with chitosan and trimethyl chitosan: impact of formulation on physicochemical and immunological characteristics. Vaccine 30, 5341-5348 (2012).
12. Dong W, Han B, Feng Y et al. Pharmacokinetics and biodegradation mechanisms of a versatile carboxymethyl derivative of chitosan in rats: in vivo and in vitro evaluation. Biomacromolecules 11, 1527-1533 (2010).
13. Shouval D. Hepatitis B vaccines. J. Hepatol. 39, S70-S76 (2003).
14. Gupta RK. Aluminum compounds as vaccine adjuvants. Adv. Drug Deliv. Rev. 32, 155-172 (1998).
15. O'Hagan DT, Ott GS, De Gregorio E, Seubert A. The mechanism of action of MF59 -an innately attractive adjuvant formulation. Vaccine 30, 4341-4348 (2012).
16. Acosta E, Nguyen T, Witthayapanyanon A, Harwell J, Sabatini D. Linker-based bio-compatible microemulsions. Environ. Sci. Technol. 39, 1275-1282 (2005).
17. He C, Hu Y, Yin L, Tang C, Yin C. Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles. Biomaterials 31, 3657-3666 (2010).
18. Henriksen-Lacey M, Christensen D, Bramwell VW et al. Liposomal cationic charge and antigen adsorption are important properties for the efficient deposition of antigen at the injection site and ability of the vaccine to induce a CMI response. J. Control. Release 145, 102-108 (2010).
19. Bal SM, Slütter B, van Riet E et al. Efficient induction of immune responses through intradermal vaccination with N-trimethyl chitosan containing antigen formulations. J. Control. Release 142, 374-383 (2010).
20. Zaki NM, Nasti A, Tirelli N. Nanocarriers for cytoplasmic delivery: cellular uptake and intracellular fate of chitosan and hyaluronic acid-coated chitosan nanoparticles in a phagocytic cell model. Macromol. Biosci. 11, 1747-1760 (2011).
21. Roser M, Fischer D, Kissel T. Surface-modified biodegradable albumin nano- and microspheres II: effect of surface charges on in vitro phagocytosis and biodistribution in rats. Eur. J. Pharm. Biopharm. 46, 255-263 (1998).
22. Foged C, Brodin B, Frokjaer S, Sundblad A. Particle size and surface charge affect particle uptake by human dendritic cells in an in vitro model. Int. J. Pharm. 298, 315-322 (2005).
23. Schoen MP, Schoen M. Imiquimod: mode of action. Br. J. Dermatol. 157, 8-13 (2007).
24. Chellat F, Grandjean-Laquerriere A, Le Naour R et al. Metalloproteinase and cytokine production by THP-1 macrophages following exposure to chitosan-DNA nanoparticles. Biomaterials 26, 961-970 (2005).
25. Liu L, Bai Y, Song C et al. The impact of arginine-modified chitosan-DNA nanoparticles on the function of macrophages. J. Nanopart. Res. 12, 1637-1644 (2010).
26. Stanley MA. Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential. Clin. Exp. Dermatol. 27, 571 (2002).
27. Moore K, Ogarra A, Malefyt R, Vieira P, Mosmann T. Interleukin-10. Annu. Rev. Immunol. 11, 165-190 (1993).
28. Wagner T, Ahonen C, Couture A et al. Modulation of Th1 and Th2 cytokine production with the immune response modifiers, R-848 and imiquimod. Cell Immunol. 191, 10-19 (1999).
29. Prego C, Paolicelli P, Diaz B et al. Chitosan-based nanoparticles for improving immunization against hepatitis B infection. Vaccine 28, 2607-2614 (2010).
30. Stoute J, Kester K, Krzych U et al. Long-term efficacy and immune responses following immunization with the RTS,S malaria vaccine. J. Infect. Dis. 178, 1139-1144 (1998).
31. Zaharoff DA, Rogers CJ, Hance KW, Schlom J, Greiner JW. Chitosan solution enhances both humoral and cell-mediated immune responses to subcutaneous vaccination. Vaccine 25, 2085-2094 (2007).
32. Wen Z, Xu Y, Zou X, Xu Z. Chitosan nanoparticles act as an adjuvant to promote both Th1 and Th2 immune responses induced by ovalbumin in mice. Marine Drugs 9, 1038-1055 (2011).
33. Tomai M, Imbertson L, Stanczak T, Tygrett L, Waldschmidt T. The immune response modifiers imiquimod and R-848 are potent activators of B lymphocytes. Cell Immunol. 203, 55-65 (2000).
34. Amidi M, Romeijn SG, Verhoef JC et al. N-trimethyl chitosan (TMC) nanoparticles loaded with influenza subunit antigen for intranasal vaccination: biological properties and immunogenicity in mouse model. Vaccine 25, 144-153 (2007).
35. Moon H, Lee J, Talactac MR et al. Mucosal immunization with recombinant influenza hemagglutinin protein and poly gamma-glutamate/chitosan nanoparticles induces protection against highly pathogenic influenza A virus. Vet. Microbiol. 160, 277-289 (2012).